CSCO guidelines for colorectal cancer version 2022: Updates and discussions.
作者信息
Yuan Zhijun, Weng Shanshan, Ye Chenyang, Hu Hanguang, Zhang Suzhan, Yuan Ying
机构信息
Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
Department of Medical Oncology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
出版信息
Chin J Cancer Res. 2022 Apr 30;34(2):67-70. doi: 10.21147/j.issn.1000-9604.2022.02.01.
Abstract
摘要
相似文献
1
CSCO guidelines for colorectal cancer version 2022: Updates and discussions.《中国临床肿瘤学会（CSCO）结直肠癌诊疗指南2022版：更新与讨论》
Chin J Cancer Res. 2022 Apr 30;34(2):67-70. doi: 10.21147/j.issn.1000-9604.2022.02.01.
2
CSCO guidelines for colorectal cancer version 2024: Updates and discussions.《2024版中国临床肿瘤学会（CSCO）结直肠癌诊疗指南：更新与讨论》
Chin J Cancer Res. 2024 Jun 30;36(3):233-239. doi: 10.21147/j.issn.1000-9604.2024.03.01.
3
Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018.《中国临床肿瘤学会（CSCO）结直肠癌诊疗指南2019版》相对于2018版的更新内容。
Chin J Cancer Res. 2019 Jun;31(3):423-425. doi: 10.21147/j.issn.1000-9604.2019.03.03.
4
Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019.《中国临床肿瘤学会（CSCO）结直肠癌诊疗指南2020》相对于2019版的更新内容。
Chin J Cancer Res. 2020 Jun;32(3):403-407. doi: 10.21147/j.issn.1000-9604.2020.03.11.
5
CSCO guidelines for colorectal cancer version 2023: Updates and insights.《2023版中国临床肿瘤学会（CSCO）结直肠癌诊疗指南：更新与见解》
Chin J Cancer Res. 2023 Jun 30;35(3):233-238. doi: 10.21147/j.issn.1000-9604.2023.03.02.
6
Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020.《中国临床肿瘤学会（CSCO）结直肠癌诊疗指南》2021年版相较于2020年版的更新内容。
Chin J Cancer Res. 2021 Jun 30;33(3):302-307. doi: 10.21147/j.issn.1000-9604.2021.03.02.
7
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version).中国临床肿瘤学会（CSCO）结直肠癌诊疗指南2018（英文版）
Chin J Cancer Res. 2019 Feb;31(1):117-134. doi: 10.21147/j.issn.1000-9604.2019.01.07.
8
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version).中国临床肿瘤学会（CSCO）头颈部癌诊疗指南2018（英文版）
Chin J Cancer Res. 2019 Feb;31(1):84-98. doi: 10.21147/j.issn.1000-9604.2019.01.05.
9
[Updates of Chinese Society of Clinical Oncology (CSCO) guideline for breast cancer in 2018].[中国临床肿瘤学会（CSCO）2018年乳腺癌诊疗指南更新]
Zhonghua Yi Xue Za Zhi. 2018 Apr 24;98(16):1213-1217. doi: 10.3760/cma.j.issn.0376-2491.2018.16.005.
10
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 (English version).中国临床肿瘤学会（CSCO）2018年分化型甲状腺癌持续/复发及转移诊疗指南（英文版）
Chin J Cancer Res. 2019 Feb;31(1):99-116. doi: 10.21147/j.issn.1000-9604.2019.01.06.
引用本文的文献
1
Updates of CSCO guidelines for colorectal cancer version 2025.《2025年版中国临床肿瘤学会（CSCO）结直肠癌诊疗指南》更新内容
Chin J Cancer Res. 2025 Jun 30;37(3):297-302. doi: 10.21147/j.issn.1000-9604.2025.03.01.
2
Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline).《2024年韩国胃癌诊疗指南：基于证据的多学科方法（2022年指南更新）》
J Gastric Cancer. 2025 Jan;25(1):5-114. doi: 10.5230/jgc.2025.25.e11.
3
CSCO guidelines for colorectal cancer version 2024: Updates and discussions.《2024版中国临床肿瘤学会（CSCO）结直肠癌诊疗指南：更新与讨论》
Chin J Cancer Res. 2024 Jun 30;36(3):233-239. doi: 10.21147/j.issn.1000-9604.2024.03.01.
4
Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study.曲氟尿苷/替匹嘧啶联合贝伐单抗对比曲氟尿苷/替匹嘧啶单药治疗难治性转移性结直肠癌的疗效与安全性：一项回顾性队列研究
J Gastrointest Oncol. 2024 Apr 30;15(2):612-629. doi: 10.21037/jgo-24-98. Epub 2024 Apr 28.
5
Distal margin distance in radical resection of locally advanced rectal cancer after neoadjuvant therapy.新辅助治疗后局部晚期直肠癌根治性切除术中的远端切缘距离
Chin J Cancer Res. 2024 Apr 30;36(2):226-232. doi: 10.21147/j.issn.1000-9604.2024.02.09.
6
Characterization of tongue coating microbiome from patients with colorectal cancer.结直肠癌患者舌苔微生物群的特征分析
J Oral Microbiol. 2024 Apr 26;16(1):2344278. doi: 10.1080/20002297.2024.2344278. eCollection 2024.
7
Association of preoperative and recurrent serum carcinoembryonic antigen and outcome of colorectal cancer patients with metastatic relapse.术前及复发时血清癌胚抗原与发生转移性复发的结直肠癌患者预后的相关性
Heliyon. 2024 Apr 6;10(7):e29347. doi: 10.1016/j.heliyon.2024.e29347. eCollection 2024 Apr 15.
8
Elevated postoperative carcinoembryonic antigen guides adjuvant chemotherapy for stage II colon cancer: a multicentre cohort retrospective study.术后癌胚抗原升高指导 II 期结肠癌辅助化疗：一项多中心队列回顾性研究。
Sci Rep. 2024 Mar 22;14(1):6889. doi: 10.1038/s41598-024-55967-w.
9
Epidemiology and early screening strategies for colorectal cancer in China.中国结直肠癌的流行病学及早期筛查策略
Chin J Cancer Res. 2023 Dec 30;35(6):606-617. doi: 10.21147/j.issn.1000-9604.2023.06.05.
10
A pan-cancer analysis of the oncogenic role of Golgi transport 1B in human tumors.高尔基体转运蛋白1B在人类肿瘤中的致癌作用的泛癌分析。
J Transl Int Med. 2023 Dec 20;11(4):433-448. doi: 10.2478/jtim-2023-0002. eCollection 2023 Dec.
本文引用的文献
1
Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis.regorafenib 联合 toripalimab 治疗转移性结直肠癌患者的 Ib/II 期临床试验及肠道微生物组分析。
Cell Rep Med. 2021 Aug 27;2(9):100383. doi: 10.1016/j.xcrm.2021.100383. eCollection 2021 Sep 21.
2
Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America.结直肠癌的发病率、死亡率、生存率、危险因素和筛查：中国、欧洲和北美之间的比较。
Cancer Lett. 2021 Dec 1;522:255-268. doi: 10.1016/j.canlet.2021.09.034. Epub 2021 Sep 24.
3
Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020.《中国临床肿瘤学会（CSCO）结直肠癌诊疗指南》2021年版相较于2020年版的更新内容。
Chin J Cancer Res. 2021 Jun 30;33(3):302-307. doi: 10.21147/j.issn.1000-9604.2021.03.02.
4
Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.术后循环肿瘤 DNA 作为 II 期至 III 期结直肠癌复发风险的标志物。
J Hematol Oncol. 2021 May 17;14(1):80. doi: 10.1186/s13045-021-01089-z.
5
Colorectal cancer burden and trends: Comparison between China and major burden countries in the world.结直肠癌负担与趋势：中国与世界主要负担国家的比较。
Chin J Cancer Res. 2021 Feb 28;33(1):1-10. doi: 10.21147/j.issn.1000-9604.2021.01.01.
6
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
7
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.辅助化疗双联方案（3 个月或 6 个月）在高危 II 期结直肠癌患者中的应用。
J Clin Oncol. 2021 Feb 20;39(6):631-641. doi: 10.1200/JCO.20.01330. Epub 2021 Jan 13.
8
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.帕博利珠单抗治疗微卫星高度不稳定型晚期结直肠癌。
N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.
9
National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version).《中国结直肠癌诊疗规范（2020年版）》英文版本
Chin J Cancer Res. 2020 Aug;32(4):415-445. doi: 10.21147/j.issn.1000-9604.2020.04.01.
10
Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019.《中国临床肿瘤学会（CSCO）结直肠癌诊疗指南2020》相对于2019版的更新内容。
Chin J Cancer Res. 2020 Jun;32(3):403-407. doi: 10.21147/j.issn.1000-9604.2020.03.11.
Zotero 插件